Butnaru, T.; Mihălţan, F.D.; Bivolaru, S.; Constantin, A. Isoniazid-Resistant Tuberculosis - A Series of Clinical Cases. Internal Medicine 2023, 20, 85–96, doi:10.2478/inmed-2023-0271.
Butnaru, T.; Mihălţan, F.D.; Bivolaru, S.; Constantin, A. Isoniazid-Resistant Tuberculosis - A Series of Clinical Cases. Internal Medicine 2023, 20, 85–96, doi:10.2478/inmed-2023-0271.
Butnaru, T.; Mihălţan, F.D.; Bivolaru, S.; Constantin, A. Isoniazid-Resistant Tuberculosis - A Series of Clinical Cases. Internal Medicine 2023, 20, 85–96, doi:10.2478/inmed-2023-0271.
Butnaru, T.; Mihălţan, F.D.; Bivolaru, S.; Constantin, A. Isoniazid-Resistant Tuberculosis - A Series of Clinical Cases. Internal Medicine 2023, 20, 85–96, doi:10.2478/inmed-2023-0271.
Abstract
The emergence of M. tuberculosis strains resistant to Isoniazid (INH) and Rifampicin (RIF), the two most potent drugs of first-line anti-TB therapy is termed multidrug drug-resistant TB (MDR-TB). Multidrug-resistant tuberculosis has been a serious medical and epidemic problem all over the world. We present here a series of clinical cases consist of two patients diagnosed with isoniazid resistant tuberculosis. Histopathological examination supports the diagnosis of tuberculous granulomas. And the pathology molecular examination revealed the presence of Isoniazid-resistant Mycobacterium tuberculosis1,2 via the following mutation c.947G>A; p.Gly316Asp. Isoniazid-resistance is associated with mutations in the furA-katG and fabG1-inhA operons, as well as mutations in the ahpC gene. 64% of the isoniazid-resistance phenotypes were associated with the katG315 mutation worldwide. The second most common mutation is inhA-15, and it has been reported in 19% of the Isoniazid-resistant isolates. The significant association between the two mutations, inhA c-15 and katG 315 respectively, and the high-level resistance is of interest in the interpretation of current and future molecular diagnostic testing, as an early prediction of the level of Isoniazid-resistance is essential to decide the benefit of high-dose Isoniazid use.
Medicine and Pharmacology, Pulmonary and Respiratory Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
